徐少华, 王伟, 柳相珍. 国产吉西他滨联合卡铂治疗老年晚期非小细胞肺癌的临床观察[J]. 中国肿瘤临床, 2006, 33(1): 35-37.
引用本文: 徐少华, 王伟, 柳相珍. 国产吉西他滨联合卡铂治疗老年晚期非小细胞肺癌的临床观察[J]. 中国肿瘤临床, 2006, 33(1): 35-37.
shu
Xu Shaohua, Wang Wei, Liu Xiangzhen. Clinical Studies on the Therapy of Advanced Non-small Cell Lung Cancer (NSCLC) in the Elderly Using Domestic Gemcitabine in Combination with Carboplatin[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 33(1): 35-37.
Citation: Xu Shaohua, Wang Wei, Liu Xiangzhen. Clinical Studies on the Therapy of Advanced Non-small Cell Lung Cancer (NSCLC) in the Elderly Using Domestic Gemcitabine in Combination with Carboplatin[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 33(1): 35-37.
shu

国产吉西他滨联合卡铂治疗老年晚期非小细胞肺癌的临床观察

Clinical Studies on the Therapy of Advanced Non-small Cell Lung Cancer (NSCLC) in the Elderly Using Domestic Gemcitabine in Combination with Carboplatin

    摘要
  • 摘要: 目的:观察国产吉西他滨联合卡铂治疗老年人晚期非小细胞肺癌(NSCLC)的临床疗效和不良反应。方法:64例患者随机分为两组:A组:吉西他滨1000mg/m2于第1,8天静脉滴注,卡铂(CBP)300mg/m2静脉滴注,第1天。每28天为1周期。B组:CBP300mg/m2静脉滴注,第1天,足叶乙甙(VP-16)80mg/m2于第1～3天静脉滴注,每28天为1周期。治疗2周期后评价疗效和不良反应。结果:64例患者中可评价疗效病例61例。A组30例中,14例(46.7%)达PR;B组31例中,7例(22.5%)达PR,A组疗效显著高于B组(P<0.05)。第二周期后有62例患者可评价不良反应。最常见的不良反应为骨髓抑制,Ⅲ～Ⅳ度血小板和白细胞下降发生率A组分别为22.6%和32.3%,B组均为12.9%。其余不良反应轻微,可耐受。结论:国产吉西他滨联合卡铂治疗老年人晚期非小细胞肺癌(NSCLC)是有效安全的。

     

    Abstract: Objective: To evaluate the efficacy and safety of domestic Gemcitabine in combination with carboplatin on advanced non-small cell lung cancer in the elderly. Methods: A total of 64 patients with NSCLC were randomized into two groups, i.e. 32 cases in Group A, gemecitabine 1000 mg/ m2 was infused on D1 and 8 and carboplatin 300mg/m2 infused on D1, with 28 days one cycle; There were 32 cases in Group B, and carboplatin 300 mg/m2 was infused on D1, VP-16 80mg/m2 given on D1 to D3, with 28 days a cycle. The patient of each groups received at least 2 cycles, then the efficacy and adverse effect were appraised. Results: Sixty-one patients can be included for response rate. PR was observed in 14/30 (46.7%) in group A and 7/31(22.5%) in group B. The response rate in group A was significantly higher than in group B. The toxicity was found in sixty-two patients who received the second cycle of treatment. The main adverse effect were thrombocytopenia (incidence of 22.6% in Group A and 12.9% in Group B, with grade Ⅲ+Ⅳ) and leukopenia (incidence of 32.3% in Group A and 12.9% in Group B with grade Ⅲ+Ⅳ). Conclusion: The domestic Gemcitabine in combination with carboplatin is safe and effective in the treatment on advanced NSCLC in elderly.

     

    • HTML全文
    • 参考文献(1)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回